RXRX
RECURSION PHARMACEUTICALS, INC.
RECURSION PHARMACEUTICALS, INC. (RXRX) has 20 SEC Form 4 filings (24 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 9, 2026.
Insiders have net sold $661K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Najat Khan
- Employees:800
- HQ:Salt Lake City, UT, US
- IPO:2021-04-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$661K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$1.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 40,000 | $159K | Jul 9 | SEC ↗ | |
| Director | Sale | 3,963 | $13K | Jun 22 | SEC ↗ | |
| Director | Sale | 40,000 | $145K | Jun 5 | SEC ↗ | |
Khan NajatFirst filing | CEO and President | Sale | 23,588 | $84K | Jun 5 | SEC ↗ |
Borgeson BlakeFirst filing | Director | Sale | 30,000 | $110K | Jun 4 | SEC ↗ |
Bumpus NamandjeFirst filing | Director | Sale | 4,386 | $16K | Jun 4 | SEC ↗ |
Gibson ChristopherFirst filing | Director | Sale | 40,000 | $135K | May 8 | SEC ↗ |
Related companies
RECURSION PHARMACEUTICALS, INC. is in the Healthcare sector.